TW202016317A - 抗體藥物結合物之感受性標記 - Google Patents

抗體藥物結合物之感受性標記 Download PDF

Info

Publication number
TW202016317A
TW202016317A TW108130044A TW108130044A TW202016317A TW 202016317 A TW202016317 A TW 202016317A TW 108130044 A TW108130044 A TW 108130044A TW 108130044 A TW108130044 A TW 108130044A TW 202016317 A TW202016317 A TW 202016317A
Authority
TW
Taiwan
Prior art keywords
gene
htrop2
value
log
judged
Prior art date
Application number
TW108130044A
Other languages
English (en)
Chinese (zh)
Inventor
岡嶌大祐
安田哲
榎本圭
Original Assignee
日商第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一三共股份有限公司 filed Critical 日商第一三共股份有限公司
Publication of TW202016317A publication Critical patent/TW202016317A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8827—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW108130044A 2018-08-23 2019-08-22 抗體藥物結合物之感受性標記 TW202016317A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-156449 2018-08-23
JP2018156449 2018-08-23

Publications (1)

Publication Number Publication Date
TW202016317A true TW202016317A (zh) 2020-05-01

Family

ID=69591927

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108130044A TW202016317A (zh) 2018-08-23 2019-08-22 抗體藥物結合物之感受性標記

Country Status (6)

Country Link
US (1) US12312641B2 (https=)
EP (1) EP3842546A4 (https=)
JP (1) JP7481255B2 (https=)
CN (1) CN112739826A (https=)
TW (1) TW202016317A (https=)
WO (1) WO2020040245A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288485B2 (en) * 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
CN119490585B (zh) * 2024-12-03 2025-09-23 河南农业大学 一种抗猪源slfn11蛋白单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
CA2542656A1 (en) 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US20080131428A1 (en) 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2011155579A1 (ja) 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Ｔｒｏｐ－２抗体
TWI495644B (zh) 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途

Also Published As

Publication number Publication date
JP7481255B2 (ja) 2024-05-10
US20210340628A1 (en) 2021-11-04
JPWO2020040245A1 (ja) 2021-09-02
EP3842546A4 (en) 2022-06-29
US12312641B2 (en) 2025-05-27
EP3842546A1 (en) 2021-06-30
WO2020040245A1 (ja) 2020-02-27
CN112739826A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
US20240011098A1 (en) Diagnostic and therapeutic methods for cancer
JP7481255B2 (ja) 抗体薬物複合体の感受性マーカー
CN106456694B (zh) 与循环肿瘤细胞相关的方法和测定法
CN110546277A (zh) 用于癌症的诊断和治疗方法
US20180010132A1 (en) Inhibition of prmt5 to treat mtap-deficiency-related diseases
JP2019131546A (ja) がん患者におけるがんの治療方法及び薬物応答性の予測方法
CN110088136A (zh) 使用基因表达签名预测黑素瘤中对于ctla4封锁的应答和耐药性的组合物和方法
AU2017266686A1 (en) Markers selectively deregulated in tumor-infiltrating regulatory T cells
US20200123258A1 (en) Targeting b cells to enhance response to immune checkpoint blockade
KR20200005540A (ko) 암의 진단 및 치료 방법
EP3004396B1 (en) Compositions for the treatment of cancer
CN107002119A (zh) 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
US11851712B2 (en) Replication stress response biomarkers for immunotherapy response
JP2024513692A (ja) グレムリン１アンタゴニストを使用して疾患を処置する方法
CN107488737A (zh) 一种检测外周血tcr可变区编码基因的液体活检试剂盒及其应用
WO2012076582A1 (en) Agtr1 as a marker for bevacizumab combination therapies
US11525008B2 (en) Methods and pharmaceutical compositions for the treatment of lung cancer
JP7777533B2 (ja) Ｎｒｇ１融合体を有するがんの治療のためのポジオチニブの使用
JP2024512395A (ja) がんの治療のための方法
JP2023548590A (ja) 小細胞肺がんの分類と治療のための方法およびシステム
JP2023510847A (ja) 癌の治療方法
WO2023165618A1 (en) Methods for treating cancer
US20260108602A1 (en) Methods and systems for improving anti-cancer therapies
CA3023980C (en) Markers selectively deregulated in tumor-infiltrating regulatory t cells
WO2024227177A2 (en) Methods for predicting effects of dose intense chemotherapy treatments